Implications for neuroprotective treatments

doi:10.1016/S0079-6123(02)35046-5

Progress in Brain Research

Volume 135, 2002, Pages 487-495

https://doi.org/10.1016/S0079-6123(02)35046-5 Get rights and content

Abstract

Pharmacological neuroprotection against the consequences of seizures can be considered as primary neuroprotection where the object is to diminish the initial insult by suppressing the seizure activity or diminishing the associated ionic fluxes (of which the entry of Na⁺ and Ca²⁺ are the most significant), and secondary neuroprotection where the target is some later event in the chain linking ionic changes to altered brain morphology or function. Thus primary neuroprotection is provided by antiepileptic drugs and compounds acting on voltage-sensitive Na⁺ and Ca²⁺ channels or on glutamate receptors (NMDA, AMPA/KA or Group I metabotropic). Secondary neuroprotection may be a result of acting on the cascade leading to necrosis (e.g. free radical scavengers, NitricOxide synthase inhibitors, CycloOxygenase-2 inhibitors) or the cascades leading to apoptosis (e.g. MAP-kinase inhibitors, caspase-3 inhibitors). Other approaches may diminish the long-term morphological and functional effects of seizures (e.g. neurotrophin-related therapies).

We need improved preclinical tests for identifying novel compounds with potential for providing secondary neuroprotection and antiepileptogenesis. Clinical trials of neuroprotective agents in chronic epilepsy in adults pose major practical difficulties but the severe childhood epilepsies provide opportunities for aggressive testing of novel compounds.

References (88)

R.M. Arida et al.
The course of untreated seizures in the pilocarpine model of epilepsy
Epilepsy Res.
(1999)
N.G. Bazan et al.
What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis
M.M. Behrens et al.
Prevention of neuronal apoptosis by phorbolester-induced activation of protein kinase C: blockade of p38 mitogen-activated protein kinase
Neuroscience
(1999)
Y. Ben-Ari
Limbic seizures and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy
Neuroscience
(1985)
D.K. Binder et al.
BDNF and epilepsy: too much of a good thing?
Trends Neurosci.
(2001)
F. Bordi et al.
Group I metabotropic glutamate receptors: implications for brain disease
Prog. Neurobiol.
(1999)
V. Bruno et al.
Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures
Eur. J. Pharmacol.
(1996)
V. Bruno et al.
Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4-carboxyphenylglycine (LY367385): comparison with LY 357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors
Neuropharmacology
(1999)
A.G. Chapman et al.
The anticonvulsant effect of the non-NMDA antagonists NBQX and GYKI 52466 in mice
Epilepsy Res.
(1991)
A.G. Chapman et al.
Anticonvulsant actions of LY367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid)
Eur. J. Pharmacol.
(1999)

A.G. Chapman et al.

Anticonvulsant activity of two metabotropic glutamate Group I antagonists selective for the mGlu5 receptor: 2methyl-6-(phenylethynyl)-pyridine(MPEP), and (E)-6-methyl2-styryl-pyridine (SIB 1893)

Neuropharmacology

(2000)

C.B. Dodrill

Progressive cognitive decline in adolescents and adults with epilepsy

N.F. Dos Santos et al.

Epileptogenesis in immature rats following recurrent status epilepticus

Brain Res. Rev.

(2000)

J.S. Duncan

MRI studies. Do seizures damage the brain?

N. Dürmüller et al.

The effect of the non-NMDA antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures

Epilepsy Res.

(1994)

R.G. Fariello et al.

Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist

Epilepsy Res.

(1989)

D.G. Fujikawa

The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus

Brain Res.

(1996)

D.G. Fujikawa et al.

The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage

Epilepsy Res.

(1994)

Y. Gilgun-Sherki et al.

Oxidative stress-induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier

Neuropharmacology

(2001)

G.V. Goddard et al.

A permanent change in brain function resulting from daily electrical stimulation

Exp. Neurol.

(1969)

T. Griffiths et al.

Status epilepticus; the reversibility of calcium loading and acute neuronal pathological changes in the rat hippocampus

Neuroscience

(1984)

E.D. Hall

Brain attack. Acute therapeutic interventions. Free radical scavengers and antioxidants

Neurosurg. Clin. N. Ana.

(1997)

T. Halonen et al.

Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats

Neuropharmacology

(2001)

U. Heinemann et al.

Cell death and metabolic activity during epileptiform discharges and status epilepticus in the hippocampus

D.C. Henshall et al.

Cleavage of Bid may amplify caspase-8-induced neuronal death following focally evoked limbic seizures

Neurobiol. Dis.

(2001)

K.H. Holmes et al.

The N-methyl-d-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures

Brain Res.

(1990)

J.L. Jankowsky et al.

The role of cytokines and growth factors in seizures and their sequelae

Prog. Neurobiol.

(2001)

F.E. Jensen et al.

Hypoxia-induced hyperexcitability in vivo and in vitro in the immature hippocampus

Epilepsy Res.

(1996)

M.E. Kelly et al.

Hippocampal kindling protects several structures from the neuronal damage resulting from kainic acid-induced status epilepticus

Brain Res.

(1994)

K. Kitagawa et al.

‘Ischemic tolerance’ phenomenon found in the brain

Brain Res.

(1990)

Z. Kokaia et al.

Seizure-induced differential expression of messenger RNAs for neurotrophins and their receptors in genetically fast and slow kindling rats

Neuroscience

(1996)

B. Kucukkaya et al.

Low dose MK-801 protects against iron-induced oxidative changes in a rat model of focal epilepsy

Brain Res.

(1998)

M. Lerner-Natoli et al.

N-[1-(2-thienyl)cyclohexyl]-piperidine (TCP) does not block kainic acid-induced status epilepticus but reduces secondary hippocampal damage

Neurosci. Lett.

(1991)

V.L. Marcheselli et al.

Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus: inhibition by a platelet-activating factor antagonist

J. Biol. Chem.

(1996)

M.A. Mikati et al.

Consequences of alpha-amino-3-hydroxy-5-methyl-4-hydroxy5-methyl-4-isoxazolepropionic acid receptor blockade during status epilepticus in the developing brain

Brain Res. Dev. Brain Res.

(1999)

P. Mohapel et al.

Differential sensitivity of various temporal lobe structures in the rat to kindling and status epilepticus induction

Epilepsy Res.

(1996)

F. Nicoletti et al.

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders

Trends Neurosci.

(1996)

J. Nissinen et al.

A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat

Epilepsy Res.

(2000)

P. Osehobo et al.

Brain-derived neurotrophic factor infusion delays amygdala and perforant path kindling without affecting paired-pulse measures of neuronal inhibition in adult rats

Neuroscience

(1999)

M. Pisa et al.

Spontaneous recurrent seizures after intracerebral injections of kainic acid in rat: a possible model of human temporal lobe epilepsy

Brain Res.

(1980)

H. Potschka et al.

Corneal kindling in mice: behavioural and pharmacological differences to conventional kindling

Epilepsy Res.

(1999)

S. Reibel et al.

Brain-derived neurotrophic factor delays hippocampal kindling in the rat

Neuroscience

(2000)

M. Sasahira et al.

Epileptic tolerance: prior seizures protect against seizure-induced neuronal injury

Neurosci. Lett.

(1995)

P. Tandon et al.

Neuroprotective effects of brain-derived neurotrophic factor in seizures during development

Neuroscience

(1999)

Cited by (69)

The prefrontal cortex shows widespread decrease in H3 histamine receptor binding densities in rats with genetic generalized epilepsies
2022, Epilepsy Research
Distributions of brain H3 histamine receptors in regions of the prefrontal cortex were studied by assessing regional binding densities for [3 H](R)α-methylhistamine in coronal brain slices of normal rats and rats with genetically determined absence and/or audiogenic epilepsies.
The three groups of epileptic rats displayed widespread significant decreases in H3 histamine receptor binding densities. A 20–25% decline was seen in the rostral aspects of the lateral prefrontal cortex, namely the granular, dysgranular, and dorsal agranular insular regions. The reduction was not specific for the epilepsy types. The same was observed in the rostral part of the primary cingulate cortex and the secondary midcingulate cortex. On borders of this core effect, several seizure-type specific declines were seen. Namely, the infralimbic, prelimbic and posterior agranular insular cortices demonstrated absence-epilepsy related reductions in the H3 histamine receptor binding densities. A decrease related to audiogenic seizures was noted in the rostral part of the piriform cortex.
The pattern of widespread and seizure-type unspecific decline in H3 histamine receptor binding densities points to a common part of brain loops underlying generalized convulsive and non-convulsive types of epilepsy. It also might hint at putative seizure-related changes in the release of histamine from specific fibers innervating the prefrontal area.
Novel treatment options for epilepsy: Focus on perampanel
2013, Pharmacological Research
Perampanel is a new chemical entity recently approved in the United States (US) and European Union (EU) as adjunctive treatment of partial-onset seizures with and without secondary generalization in patients with epilepsy aged 12 years and older. Pharmacological studies suggest that perampanel acts with a new mechanism of action via non-competitive antagonism of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor of glutamate, the main mediator of excitatory neurotransmission in the central nervous system.
Perampanel is completely absorbed after oral administration. The drug is 95% bound to plasma proteins and is extensively metabolized by oxidation followed by glucuronidation. Perampanel has an elimination half-life of approximately 52–129 h, allowing once daily dosing, with peak plasma levels observed 0.25–2 h post-dose. Randomized placebo-controlled trials of adjunctive treatment have demonstrated that once-daily perampanel doses of 4–12 mg/day significantly reduced partial-onset seizure frequency in patients with pharmacoresistant epilepsy along with a favorable tolerability profile. In perampanel pivotal trials, the most frequently reported treatment emergent adverse events (>10%) included dizziness, somnolence, fatigue and headache. Perampanel therapeutic response was maintained in patients included in the long term open-label extension studies for up to 4 years. Based on these data, perampanel offers a valuable option in the add-on treatment of partial-onset and secondarily generalized seizures.
Synthesis and configurational assignment of 1,2-dihydroimidazo[5,1-b] quinazoline-3,9-diones: Novel NMDA receptor antagonists
2012, Tetrahedron
NMDA receptors form a major subdivision of the ionotropic glutamate receptor family that mediates excitatory synaptic transmission in the brain. Series of 1-substituted 1,2-dihydroimidazo[5,1-b]quinazolinediones were synthesized and found to have potent nanomolar activity at the glycine site of the NMDA receptor. Imidazoquinazolinediones were prepared by cyclocondensation of 4-oxo-quinazoline-2-carboxamide with aldehydes and orthoesters with good yields. The formed enantiomers were separated by chiral HPLC. The absolute configuration of pure enantiomers is elucidated by combined CD/Quantumchemical time-dependent DFT calculation method (TDDFT).
The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria
2012, Molecular and Cellular Neuroscience
Citation Excerpt :
Treatment of rats with the powerful convulsant, kainic acid (KA), triggers temporal lobe epilepsy with extensive degeneration of hippocampal pyramidal cells (Ben-Ari and Cossart, 2000; Castillo et al., 1997; Nadler et al., 1978; Olney et al., 1974). Activation of KA receptor stimulates different signalling pathways resulting in the activation of various proteases, cell and organelle swelling and necrotic cell death on one side, and the activation of intrinsic mitochondrial cell death pathway on the other side (for review see Meldrum, 2002). KA induces changes in the expression of pro-and anti-apoptotic molecules, including those of the Bcl-2 family which are linked to mitochondrial dysfunction (Henshall et al., 2002; Murphy et al., 2007).
Kainic acid (KA) induced seizures provokes an extensive neuronal degeneration initiated by c-Jun N-terminal kinases (JNK) as central mediators of excitotoxicity. However, the actions of their individual isoforms in cellular organelles including mitochondria remain to be elucidated. Here, we have studied the activation of JNK1, JNK2 and JNK3 and their activators, mitogen-activated protein kinase kinase (MKK) 4/7, in brain mitochondria, cytosolic and nuclear fractions after KA seizures. In the mitochondrial fraction, KA significantly increased the presence of JNK1, JNK3 and MKK4 and stimulated their phosphorylation i.e. activation. The pro-apoptotic proteins, Bim and Bax were induced and, consequently, the ratio Bcl-2-Bax decreased. These changes were paralleled by the release of cytochrome c and cleavage of poly(ADP-ribose)-polymerase (PARP).
The JNK peptide inhibitor, D-JNKI-1 (XG-102) reversed these pathological events in the mitochondria and almost completely abolished cytochrome c release and PARP cleavage. Importantly, JNK3, but not JNK1 or JNK2, was associated with Bim in mitochondria and D-JNKI-1 prevented the formation of this apoptotic complex.
Apart from of the attenuation of c-Jun phosphorylation in the nucleus, D-JNKI-1 did not affect the level of JNK3 isoform in the nuclear and cytosolic fractions. These findings provide novel insights into the mode of action of individual JNK isoforms in cell organelles and points to the JNK3 pool in mitochondria as a target of the JNK inhibitor D-JNKI-1 to confer neuroprotection.
Deletion of puma protects hippocampal neurons in a model of severe status epilepticus
2010, Neuroscience
Citation Excerpt :
The present study explored the relationship between seizure duration, hippocampal damage and mode of cell death in a mouse model of status epilepticus. This remains an important issue since it has the potential to influence how to protect brain against seizure damage (Meldrum, 2002; Henshall and Murphy, 2008). Here, we attributed the mode of cell death as apoptosis on the basis of nuclear morphology in TUNEL-positive cells.
Prolonged seizures (status epilepticus) can activate apoptosis-associated signaling pathways. The extent to which such pathways contribute to cell death might depend on the insult intensity, whereby the programmed or apoptotic cell death component is reduced when seizures are more severe or protracted. We recently showed that mice lacking the pro-apoptotic Bcl-2 homology domain 3-only protein Puma (Bbc3) were potently protected against damage caused by status epilepticus. In the present study we examined whether Puma deficiency was protective when the seizure episode was more severe. Intra-amygdala microinjection of 1 μg kainic acid (KA) into C57BL/6 mice triggered status epilepticus that lasted about twice as long as with 0.3 μg KA prior to lorazepam termination. Hippocampal damage was also significantly greater in the higher-dose group. Over 80% of degenerating neurons after seizures were positive for DNA fragmentation assessed by terminal deoxynucleotidyl dUTP nick end labeling (TUNEL). Microscopic analysis of neuronal nuclear morphology in TUNEL-positive cells revealed the proportion displaying large rounded clumps of condensed chromatin was ∼50% lower in the high-dose versus low-dose KA group. Nevertheless, compared to heterozygous and wild-type mice subject to status epilepticus by high-dose KA, neuronal death was reduced by ∼50% in the hippocampus of Puma-deficient mice. These data suggest aspects of the apoptotic component of seizure-induced neuronal death are insult duration- or severity-dependent. Moreover, they provide further genetic evidence that seizure-induced neuronal death is preventable by targeting so-called apoptosis-associated signaling pathways and Puma loss likely disrupts caspase-independent or non-apoptotic seizure-induced neuronal death.
Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats
2009, Brain Research
Selective neuronal loss is closely associated with cognitive impairments that occur following status epilepticus (SE). Our previous study suggested that erythropoietin (Epo) pre-treatment suppressed hippocampal neuronal death in rats after 1 h of SE convulsions. However, the underlying protective mechanism remained unclear. In the present study, we investigated the anti-apoptotic mechanism of Epo pre-treatment in the hippocampus using Li-pilocarpine-induced SE in rats. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed to detect apoptosis and the Morris water maze was employed to assess spatial learning ability and to analyze the protective effects of Epo. Levels of Bcl-2 family (Bid, Bcl-2 and Bax) markers were examined via Western blot and immunofluorescence. We found that Epo pre-treatment prevented SE-induced cognitive impairments. The protection and cognitive effects were associated with higher levels of Bcl-2 and lower levels of Bax. The present results suggest that systemic Epo pre-treatment can confer neuroprotection following SE, and may provide novel insights into pathogenesis and treatment following SE injury.

View all citing articles on Scopus

View full text

Implications for neuroprotective treatments

Abstract

Epilepsy Res.

Neuroscience

Neuroscience

Trends Neurosci.

Prog. Neurobiol.

Eur. J. Pharmacol.

Neuropharmacology

Epilepsy Res.

Eur. J. Pharmacol.

Neuropharmacology

Brain Res. Rev.

Epilepsy Res.

Epilepsy Res.

Brain Res.

Epilepsy Res.

Neuropharmacology

Exp. Neurol.

Neuroscience

Neurosurg. Clin. N. Ana.

Neuropharmacology

Neurobiol. Dis.

Brain Res.

Prog. Neurobiol.

Epilepsy Res.

Brain Res.

Brain Res.

Neuroscience

Brain Res.

Neurosci. Lett.

J. Biol. Chem.

Brain Res. Dev. Brain Res.

Epilepsy Res.

Trends Neurosci.

Epilepsy Res.

Neuroscience

Brain Res.

Epilepsy Res.

Neuroscience

Neurosci. Lett.

Neuroscience